mergers-and-acquisitions News
Verisk Scraps $2.35B AccuLynx Deal Amid FTC Regulatory Logjam
Data analytics firm terminates acquisition citing a missed FTC review deadline, but AccuLynx contests the move, sparking a potential legal showdown.
J&J Finalizes $3B Halda Deal, Eyes Cancer Dominance
Acquisition of Halda Therapeutics bolsters oncology pipeline but triggers a projected $0.20 near-term dilution to adjusted earnings per share.
DigitalBridge Skyrockets Over 40% on SoftBank Advanced Acquisition Talks
The digital infrastructure firm, managing a $108 billion portfolio, could be acquired by the Japanese conglomerate as part of its major push into AI-related investments.
Brookfield Nears £4.5bn Center Parcs Stake Sale to UK Pension Group
The deal, which values the holiday village operator substantially higher than its 2015 purchase price, validates the asset manager's capital recycling strategy.
Dynavax Shares Surge 39% on $2.2 Billion Sanofi Buyout
French drugmaker pays a steep premium for Dynavax's growing Hepatitis B vaccine and a promising shingles candidate to challenge GSK's market leader.
Alkermes Wins Bidding War for Avadel with $2.1B Deal
A revised $22.50 per share offer from Alkermes edged out a competing proposal from H. Lundbeck A/S, concluding a dramatic takeover battle for the narcolepsy drugmaker.
Repare Therapeutics Jumps 20% on $30M Gilead Asset Sale
The deal to sell a cancer drug candidate sweetens the terms of Repare's pending acquisition, boosting the cash payout for shareholders.
Sanofi to Acquire Dynavax for $2.2 Billion, Boosting Vaccine Unit
The all-cash deal, a 39% premium for Dynavax shareholders, adds the fast-growing HEPLISAV-B hepatitis B vaccine to the French drugmaker's portfolio.